{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:11:27Z","timestamp":1778206287579,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01398-x","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T01:20:02Z","timestamp":1769390402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Yttrium-90 Transarterial Radioembolization for Intrahepatic Cholangiocarcinoma: A Comprehensive Review"],"prefix":"10.1007","volume":"57","author":[{"given":"Arsalan","family":"Nadeem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Abu","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashima","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna","family":"Kalyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Borja-Cacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Dietch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kulik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"issue":"9935","key":"1398_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(13)61903-0.","journal-title":"Lancet"},{"issue":"6","key":"1398_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2014.01.021.","journal-title":"J Hepatol"},{"issue":"1","key":"1398_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e318176c4d3.","journal-title":"Ann Surg"},{"issue":"3","key":"1398_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101290","volume":"7","author":"Z Li","year":"2025","unstructured":"Li Z, Aliseda D, Jones O, et al. Recent advances in systemic therapy for advanced biliary tract cancer: a systematic review and meta-analysis using reconstructed RCT survival data. JHEP Rep Innov Hepatol. 2025;7(3):101290. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101290.","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"1","key":"1398_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma. JAMA Oncol. 2020;6(1):51\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1398_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00270-022-03183-2","volume":"45","author":"AN Gupta","year":"2022","unstructured":"Gupta AN, Gordon AC, Gabr A, et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for a 136-patient cohort. Cardiovasc Intervent Radiol. 2022;45(8):1117\u201328. https:\/\/doi.org\/10.1007\/s00270-022-03183-2.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"1398_CR7","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jvir.2020.06.027","volume":"31","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Scalise P, Boni G, et al. Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion: validation of the Milan prognostic score. J Vasc Interv Radiol JVIR. 2020;31(12):2028\u201332. https:\/\/doi.org\/10.1016\/j.jvir.2020.06.027.","journal-title":"J Vasc Interv Radiol JVIR"},{"issue":"3","key":"1398_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00270-023-03657-x","volume":"47","author":"P Reimer","year":"2024","unstructured":"Reimer P, Vilgrain V, Arnold D, et al. Factors impacting survival after transarterial radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: a combined analysis of the prospective CIRT studies. Cardiovasc Intervent Radiol. 2024;47(3):310\u201324. https:\/\/doi.org\/10.1007\/s00270-023-03657-x.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"1398_CR9","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1245\/s10434-014-4365-3","volume":"22","author":"M Rayar","year":"2015","unstructured":"Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol. 2015;22(9):3102\u20138. https:\/\/doi.org\/10.1245\/s10434-014-4365-3.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1398_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.adro.2016.08.003","volume":"1","author":"MA Westcott","year":"2016","unstructured":"Westcott MA, Coldwell DM, Liu DM, Zikria JF. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016;1(4):351\u201364. https:\/\/doi.org\/10.1016\/j.adro.2016.08.003.","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"1398_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1148\/radiol.11101777","volume":"260","author":"SA Kim","year":"2011","unstructured":"Kim SA, Lee JM, Lee KB, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern\u2013correlation with clinicopathologic findings. Radiology. 2011;260(1):148\u201357. https:\/\/doi.org\/10.1148\/radiol.11101777.","journal-title":"Radiology"},{"issue":"5","key":"1398_CR12","first-page":"969","volume":"30","author":"C Breedis","year":"1954","unstructured":"Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969\u201377.","journal-title":"Am J Pathol"},{"issue":"9","key":"1398_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","volume":"34","author":"B Kis","year":"2023","unstructured":"Kis B, Shridhar R, Mhaskar R, et al. Radioembolization with Yttrium-90 Glass Microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma\u2014a prospective feasibility study. J Vasc Interv Radiol. 2023;34(9):1547\u201355. https:\/\/doi.org\/10.1016\/j.jvir.2023.05.026.","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"1398_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2217\/fon-2017-0443","volume":"14","author":"L Filippi","year":"2018","unstructured":"Filippi L, Schillaci O, Cianni R, Bagni O. Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma. Future Oncol. 2018;14(9):809\u201318. https:\/\/doi.org\/10.2217\/fon-2017-0443.","journal-title":"Future Oncol"},{"issue":"11","key":"1398_CR15","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s00270-022-03215-x","volume":"45","author":"E Garin","year":"2022","unstructured":"Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial Radioembolization Dosimetry in 2022. Cardiovasc Intervent Radiol. 2022;45(11):1608\u201321. https:\/\/doi.org\/10.1007\/s00270-022-03215-x.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"1398_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0044-1779715","volume":"41","author":"A Villalobos","year":"2024","unstructured":"Villalobos A, Pisanie JLdu, Gandhi RT, Kokabi N. Yttrium-90 Radioembolization Dosimetry: dose considerations, optimization, and tips. Semin Intervent Radiol. 2024;41(1):63\u201378. https:\/\/doi.org\/10.1055\/s-0044-1779715.","journal-title":"Semin Intervent Radiol"},{"issue":"7","key":"1398_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3348\/kjr.2025.0308","volume":"26","author":"IJ Lee","year":"2025","unstructured":"Lee IJ, Kim HC. Optimizing yttrium-90 radioembolization dosimetry for hepatocellular carcinoma: a Korean perspective. Korean J Radiol. 2025;26(7):688\u2013703. https:\/\/doi.org\/10.3348\/kjr.2025.0308.","journal-title":"Korean J Radiol"},{"issue":"19","key":"1398_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193251","volume":"17","author":"S Abu Zahra","year":"2025","unstructured":"Abu Zahra S, Nadeem A, Kundu A, et al. Recent advances in ablative therapies for hepatocellular carcinoma. Cancers. 2025;17(19):3251. https:\/\/doi.org\/10.3390\/cancers17193251.","journal-title":"Cancers"},{"issue":"4","key":"1398_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jvir.2024.12.016","volume":"36","author":"AN Gupta","year":"2025","unstructured":"Gupta AN, Serhal M, Gordon AC, et al. Radiation segmentectomy and modified radiation lobectomy for unresectable early-stage intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2025;36(4):650\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2024.12.016.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1398_CR20","doi-asserted-by":"publisher","first-page":"e240333","DOI":"10.1148\/radiol.240333","volume":"316","author":"RJ Lewandowski","year":"2025","unstructured":"Lewandowski RJ, Serhal M, Padia SA, et al. The evolving application of radiation segmentectomy for the treatment of hepatic malignancy. Radiology. 2025;316(1):e240333. https:\/\/doi.org\/10.1148\/radiol.240333.","journal-title":"Radiology"},{"issue":"1","key":"1398_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatol Baltim Md. 2014;60(1):192\u2013201. https:\/\/doi.org\/10.1002\/hep.27057.","journal-title":"Hepatol Baltim Md"},{"issue":"7","key":"1398_CR22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00261-017-1354-6","volume":"43","author":"AF Ahmed","year":"2018","unstructured":"Ahmed AF, Samreen N, Grajo JR, et al. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma. Abdom Radiol N Y. 2018;43(7):1825\u201336. https:\/\/doi.org\/10.1007\/s00261-017-1354-6.","journal-title":"Abdom Radiol N Y"},{"issue":"2","key":"1398_CR23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580\u20133. https:\/\/doi.org\/10.1007\/s00259-020-04976-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1398_CR24","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342\u201352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"issue":"1","key":"1398_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03242-3","volume":"16","author":"E Garita","year":"2025","unstructured":"Garita E, Sarwar A, Tahir M, et al. Yttrium90-TARE with or without chemotherapy may improve survival in patients with locally advanced unresectable intrahepatic cholangiocarcinoma. Discov Oncol. 2025;16(1):1386. https:\/\/doi.org\/10.1007\/s12672-025-03242-3.","journal-title":"Discov Oncol"},{"issue":"4","key":"1398_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2967\/jnumed.122.264598","volume":"64","author":"BM Schaarschmidt","year":"2023","unstructured":"Schaarschmidt BM, Kloeckner R, Dertnig T, et al. Real-life experience in the treatment of intrahepatic cholangiocarcinoma by 90Y radioembolization: a multicenter retrospective study. J Nucl Med. 2023;64(4):529\u201335. https:\/\/doi.org\/10.2967\/jnumed.122.264598.","journal-title":"J Nucl Med"},{"issue":"4","key":"1398_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jvir.2022.10.042","volume":"34","author":"TJ Robinson","year":"2023","unstructured":"Robinson TJ, Du L, Matsuoka L, et al. Survival and toxicities after yttrium-90 transarterial radioembolization of cholangiocarcinoma in the RESiN registry. J Vasc Interv Radiol. 2023;34(4):694-701.e3. https:\/\/doi.org\/10.1016\/j.jvir.2022.10.042.","journal-title":"J Vasc Interv Radiol"},{"key":"1398_CR28","doi-asserted-by":"publisher","DOI":"10.4274\/dir.2024.242929","author":"S Sozutok","year":"2025","unstructured":"Sozutok S, Pi\u015fkin FC, Ball\u0131 HT, et al. Evaluating the prognostic impact of inflammatory markers on treatment outcomes in patients with intrahepatic cholangiocarcinoma undergoing radioembolization. Diagn Interv Radiol. 2025. https:\/\/doi.org\/10.4274\/dir.2024.242929.","journal-title":"Diagn Interv Radiol"},{"issue":"7","key":"1398_CR29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jvir.2020.02.008","volume":"31","author":"S Buettner","year":"2020","unstructured":"Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis. J Vasc Interv Radiol. 2020;31(7):1035-1043.e2. https:\/\/doi.org\/10.1016\/j.jvir.2020.02.008.","journal-title":"J Vasc Interv Radiol"},{"issue":"8","key":"1398_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jvir.2019.03.018","volume":"30","author":"J White","year":"2019","unstructured":"White J, Carolan-Rees G, Dale M, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational study. J Vasc Interv Radiol JVIR. 2019;30(8):1185\u201392. https:\/\/doi.org\/10.1016\/j.jvir.2019.03.018.","journal-title":"J Vasc Interv Radiol JVIR"},{"issue":"11","key":"1398_CR31","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1007\/s00259-019-04427-z","volume":"46","author":"H Levillain","year":"2019","unstructured":"Levillain H, Duran Derijckere I, Ameye L, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270\u20139. https:\/\/doi.org\/10.1007\/s00259-019-04427-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1398_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00432-016-2291-4","volume":"143","author":"Z Jia","year":"2017","unstructured":"Jia Z, Paz-Fumagalli R, Frey G, Sella DM, McKinney JM, Wang W. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. J Cancer Res Clin Oncol. 2017;143(3):481\u20139. https:\/\/doi.org\/10.1007\/s00432-016-2291-4.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1398_CR33","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","volume":"36","author":"S Rafi","year":"2013","unstructured":"Rafi S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440\u20138. https:\/\/doi.org\/10.1007\/s00270-012-0463-4.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"1398_CR34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","volume":"17","author":"A Saxena","year":"2010","unstructured":"Saxena A, Bester L, Chua TC, Chu FC. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484\u201391. https:\/\/doi.org\/10.1245\/s10434-009-0777-x.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1398_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","volume":"35","author":"RT Hoffmann","year":"2012","unstructured":"Hoffmann RT, Paprottka PM, Sch\u00f6n A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105\u201316. https:\/\/doi.org\/10.1007\/s00270-011-0142-x.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"1398_CR36","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jvir.2018.04.001","volume":"29","author":"A Gangi","year":"2018","unstructured":"Gangi A, Shah J, Hatfield N, et al. Intrahepatic cholangiocarcinoma treated with transarterial Yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interv Radiol. 2018;29(8):1101\u20138. https:\/\/doi.org\/10.1016\/j.jvir.2018.04.001.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1398_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010056","volume":"9","author":"M K\u00f6hler","year":"2019","unstructured":"K\u00f6hler M, Harders F, Loh\u00f6fer F, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9(1):56. https:\/\/doi.org\/10.3390\/jcm9010056.","journal-title":"J Clin Med"},{"issue":"21","key":"1398_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215324","volume":"14","author":"I Schatka","year":"2022","unstructured":"Schatka I, Jochens HV, Rogasch JMM, et al. Transarterial yttrium-90 radioembolization in intrahepatic cholangiocarcinoma patients: outcome assessment applying a prognostic score. Cancers. 2022;14(21):5324. https:\/\/doi.org\/10.3390\/cancers14215324.","journal-title":"Cancers"},{"issue":"5","key":"1398_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1159\/000525489","volume":"11","author":"SL Chan","year":"2022","unstructured":"Chan SL, Chotipanich C, Choo SP, et al. Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial. Liver Cancer. 2022;11(5):451\u20139. https:\/\/doi.org\/10.1159\/000525489.","journal-title":"Liver Cancer"},{"issue":"6","key":"1398_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jvir.2022.02.016","volume":"33","author":"DA Schartz","year":"2022","unstructured":"Schartz DA, Porter M, Schartz E, et al. Transarterial yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol. 2022;33(6):679\u201386. https:\/\/doi.org\/10.1016\/j.jvir.2022.02.016.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1398_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","volume":"41","author":"DP Al-Adra","year":"2015","unstructured":"Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015;41(1):120\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2014.09.007.","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"1398_CR42","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/RLU.0000000000000904","volume":"40","author":"J Edeline","year":"2015","unstructured":"Edeline J, Du FL, Rayar M, et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med. 2015;40(11):851\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000000904.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"1398_CR43","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jvir.2021.08.009","volume":"32","author":"A Sarwar","year":"2021","unstructured":"Sarwar A, Ali A, Ljuboja D, et al. Neoadjuvant yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2021;32(11):1560\u20138. https:\/\/doi.org\/10.1016\/j.jvir.2021.08.009.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"1398_CR44","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jvir.2022.12.017","volume":"34","author":"O Ahmed","year":"2023","unstructured":"Ahmed O, Yu Q, Patel M, et al. Yttrium-90 radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2023;34(4):702\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2022.12.017.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"1398_CR45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/bjc.2016.191","volume":"115","author":"C Mosconi","year":"2016","unstructured":"Mosconi C, Gramenzi A, Ascanio S, et al. Yttrium-90 radioembolization for unresectable\/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. 2016;115(3):297\u2013302. https:\/\/doi.org\/10.1038\/bjc.2016.191.","journal-title":"Br J Cancer"},{"issue":"10","key":"1398_CR46","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","volume":"27","author":"D Riby","year":"2020","unstructured":"Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020;27(10):3729\u201337. https:\/\/doi.org\/10.1245\/s10434-020-08486-7.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1398_CR47","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","volume":"43","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol. 2020;43(9):1305\u201314. https:\/\/doi.org\/10.1007\/s00270-020-02569-4.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"20","key":"1398_CR48","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.18632\/oncotarget.28060","volume":"12","author":"R Paz-Fumagalli","year":"2021","unstructured":"Paz-Fumagalli R, Core J, Padula C, et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget. 2021;12(20):2075\u201388. https:\/\/doi.org\/10.18632\/oncotarget.28060.","journal-title":"Oncotarget"},{"issue":"5","key":"1398_CR49","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jceh.2022.03.008","volume":"12","author":"P Kumar","year":"2022","unstructured":"Kumar P, Mhaskar R, Kim R, et al. Unresectable intrahepatic cholangiocarcinoma treated with radiation segmentectomy\/lobectomy using yttrium 90-labeled glass microspheres. J Clin Exp Hepatol. 2022;12(5):1259\u201363. https:\/\/doi.org\/10.1016\/j.jceh.2022.03.008.","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"1398_CR50","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.21037\/jgo-23-210","volume":"14","author":"S Young","year":"2023","unstructured":"Young S, Torkian P, Flanagan S, D\u2019Souza D, Sanghvi T, Golzarian J. Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization. J Gastrointest Oncol. 2023;14(5):2202\u201311. https:\/\/doi.org\/10.21037\/jgo-23-210.","journal-title":"J Gastrointest Oncol"},{"issue":"11","key":"1398_CR51","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.jvir.2023.07.028","volume":"34","author":"Q Yu","year":"2023","unstructured":"Yu Q, Patel M, Kwak D, et al. Segmental yttrium-90 radioembolization using glass microspheres greater than 400 gray for the treatment of intrahepatic cholangiocarcinoma: a preliminary experience. J Vasc Interv Radiol. 2023;34(11):1970-1976.e1. https:\/\/doi.org\/10.1016\/j.jvir.2023.07.028.","journal-title":"J Vasc Interv Radiol"},{"key":"1398_CR52","doi-asserted-by":"publisher","unstructured":"Banales JM, Rodrigues PM, Aff\u00f2 S, et al. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nat Rev Gastroenterol Hepatol. 2025(1). https:\/\/doi.org\/10.1038\/s41575-025-01153-w.","DOI":"10.1038\/s41575-025-01153-w"},{"issue":"4","key":"1398_CR53","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1007\/s00330-023-10203-3","volume":"34","author":"Q Yu","year":"2024","unstructured":"Yu Q, Ungchusri E, Pillai A, et al. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024;34(4):2374\u201383. https:\/\/doi.org\/10.1007\/s00330-023-10203-3.","journal-title":"Eur Radiol"},{"issue":"3","key":"1398_CR54","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00259-018-4199-5","volume":"46","author":"H Bourien","year":"2019","unstructured":"Bourien H, Palard X, Rolland Y, et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;46(3):669\u201376. https:\/\/doi.org\/10.1007\/s00259-018-4199-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1398_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101279","volume":"7","author":"N Adamus","year":"2025","unstructured":"Adamus N, Edeline J, Henriques J, et al. First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: the French ACABi GERCOR PRONOBIL cohort. JHEP Rep. 2025;7(2):101279. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101279.","journal-title":"JHEP Rep"},{"issue":"10","key":"1398_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.05.014","volume":"49","author":"A Dhote","year":"2023","unstructured":"Dhote A, Tzedakis S, Hobeika C, et al. Impact of induction therapy in locally advanced intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2023;49(10):106939. https:\/\/doi.org\/10.1016\/j.ejso.2023.05.014.","journal-title":"Eur J Surg Oncol"},{"key":"1398_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13641","volume":"37","author":"M Maspero","year":"2024","unstructured":"Maspero M, Sposito C, Bongini MA, et al. Liver transplantation for intrahepatic cholangiocarcinoma after chemotherapy and radioembolization: an intention-to-treat study. Transplant Int. 2024;37:13641. https:\/\/doi.org\/10.3389\/ti.2024.13641.","journal-title":"Transplant Int"},{"issue":"3","key":"1398_CR58","first-page":"151","volume":"20","author":"S Kodali","year":"2024","unstructured":"Kodali S, Connor AA, Brombosz EW, Ghobrial RM. Update on the screening, diagnosis, and management of cholangiocarcinoma. Gastroenterol Hepatol. 2024;20(3):151\u20138.","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"1398_CR59","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ajt.16906","volume":"22","author":"RR McMillan","year":"2022","unstructured":"McMillan RR, Javle M, Kodali S, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. 2022;22(3):823\u201332. https:\/\/doi.org\/10.1111\/ajt.16906.","journal-title":"Am J Transplant"},{"key":"1398_CR60","doi-asserted-by":"publisher","unstructured":"Paprottka KJ, Gali\u00e8 F, Ingrisch M, et al. Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors. https:\/\/doi.org\/10.3390\/cancers13215399.","DOI":"10.3390\/cancers13215399"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01398-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T01:20:03Z","timestamp":1769390403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01398-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01398-x","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable\/required as this is a review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Aparna Kalyan reports consulting fees from Genentech, AstraZeneca, and Eisai and payment or honoraria for speaker\u2019s bureaus from Genentech and AstraZeneca and for educational events from Tempus and Eisai. She also reports honorarium payments from Deciphera Pharmaceuticals and travel and lodging payments from AstraZeneca. Laura Kulik reports advisory\/consulting fees from AstraZeneca, Eisai, Fujifilm, and Genetech\/Roche. Andrew C. Gordon reports grant funding from the Radiologial Society of North America (RSNA). Robert J. Lewandowski reports grant from National Institutes of Health (R01CA233878); reports consulting fees from ABK Medical, Boston Scientific, BD, Varian, AstraZeneca, Eisai, and Genentech; and reports stock or stock options in ABK Medical. The remaining authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}